| Obizur (susoctocog alfa) / Takeda, Ipsen |
NCT02610127: Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A |
|
|
| Completed | N/A | 53 | US | OBIZUR, rpFVIII, Recombinant pFVIII, Antihemophilic Factor (Recombinant), Porcine Sequence | Baxalta now part of Shire, Baxalta Innovations GmbH, now part of Shire | Acquired Hemophilia A | 06/19 | 06/19 | | |
NCT01968655: Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies |
|
|
| No Longer Available | N/A | | US | OBI-1, B-Domain Deleted Recombinant Porcine Factor VIII | Baxalta now part of Shire | Acquired Hemophilia A | | | | |
NCT03199794: Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice |
|
|
| Completed | N/A | 50 | Europe, US | OBIZUR, Recombinant pFVIII, Porcine Sequence, rpFVIII, Antihemophilic Factor (Recombinant) | Baxalta now part of Shire, Baxalta Innovations GmbH, now part of Shire | Acquired Hemophilia A | 07/21 | 07/21 | | |
NCT06461533: A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A |
|
|
| Recruiting | N/A | 25 | Japan | Susoctocog Alfa (Genetical Recombination), OBIZUR Intravenous Injection 500, TAK-672 | Takeda | Acquired Hemophilia A | 10/29 | 10/29 | | |
